Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
The Medical College of Georgia scientists have early evidence that HBI-002, a low-dose oral compound, can safely reduce oxidative stress and inflammation in the retina, both early, major contributors to diabetic retinopathy.
New biomarkers found in the eyes could unlock the key to helping manage diabetic retinopathy, and perhaps even diabetes, according to new research conducted at the Indiana University School of Optometry.
A National Eye Institute-funded project at Duke University has yielded a fully automated optical coherence tomography (OCT) device that does not require a trained operator and promises to broaden access to retinal imaging technology.
Early treatment with anti-VEGF injections slowed diabetic retinopathy in a clinical study from the DRCR Retina Network (DRCR.net). However, two years into the four-year study its effect on vision was similar to standard treatment.
Scientists have found that RUNX1 inhibition presents a new therapeutic approach in the treatment of age-related macular degeneration (AMD), which is the leading cause of blindness in the elderly worldwide.
Scientists at the University of Utah have invented a method for synthesizing large enough quantities of very-long-chain polyunsaturated fatty acids (VLC-PUFAs) to evaluate their potential sight-preserving properties.
Surgical and injectable drug approaches are equally effective for treatment of bleeding inside the eye from proliferative diabetic retinopathy (PDR), according to a National Eye Institute (NEI)-supported clinical study from the DRCR Retina Network .